Access Vascular, Inc

Access Vascular, Inc manufactures vascular access devices designed to reduce complications associated with indwelling catheters. The company's primary product portfolio includes HydroPICC® (peripherally inserted central catheter) and HydroMID® (midline catheter) systems, both featuring the company's proprietary MIMIX® hydrophilic biomaterial technology. The MIMIX technology is engineered to mitigate thrombosis, a leading cause of catheter-related complications including occlusions and infections. Access Vascular's devices represent an alternative to standard polyurethane catheters and competing anti-thrombogenic/anti-microbial coated alternatives. The company emphasizes clinically demonstrated, statistically significant reductions in complications through in vitro, in vivo, and clinical data. Products are marketed toward acute care hospitals and clinical settings requiring central and midline vascular access. The company has published economic analyses suggesting potential savings of up to $1.8 million for large acute care hospitals through reduced device replacements and associated complications. Access Vascular's approach relies on intrinsic biomaterial properties rather than surface coatings or fillers. The devices target improved patient experience by reducing unnecessary needle sticks and treatment delays caused by device failure or replacement.